**
In a significant revelation, internal records have uncovered a meeting between top officials from the Trump administration’s Environmental Protection Agency (EPA) and Bayer’s CEO Bill Anderson. This June 17, 2025, encounter raises serious questions about the influence of corporate interests on public health regulations, particularly concerning glyphosate, a widely used herbicide linked to cancer allegations.
High-Stakes Meeting
The meeting, which took place just months before a series of actions by the Trump administration aimed at bolstering Bayer’s position in an ongoing legal battle, involved key EPA officials such as Lee Zeldin, the agency’s administrator, and Nancy Beck, the principal deputy assistant administrator in the Office of Chemical Safety and Pollution Prevention. The gathering was reportedly convened to discuss “litigation” matters, specifically Bayer’s strategy regarding their glyphosate products, including the flagship herbicide, Roundup.
Bayer is currently facing numerous lawsuits from individuals claiming that their health was adversely affected by glyphosate exposure. These lawsuits have resulted in significant financial repercussions for the company, with settlements and jury verdicts costing them billions. At the heart of these legal claims lies the assertion that Bayer failed to adequately warn consumers about the potential cancer risks associated with their products.
Administration Support for Bayer
Documents obtained through a Freedom of Information Act request indicate that the June meeting was part of a broader strategy by the Trump administration to support Bayer in its Supreme Court fight. Following this meeting, the administration took several actions that appeared to align with Bayer’s interests, including a significant filing by the Trump-appointed solicitor general, D John Sauer, recommending that the Supreme Court hear Bayer’s case.
Moreover, the White House invoked the Defense Production Act to ensure the continued production of glyphosate herbicides, thereby providing what critics describe as undue protection to a major pesticide manufacturer. This included a recent amicus brief filed by Sauer, which solidified the government’s backing of Bayer’s legal position.
Controversy Over Corporate Influence
Critics of these developments express alarm over the apparent prioritisation of corporate interests over public health. Nathan Donley, the environmental health science director for the Center for Biological Diversity, articulated concerns regarding the extent of corporate influence, stating, “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans.”
Legal experts have echoed these sentiments, highlighting the troubling implications of such high-level meetings. Whitney Di Bona, a consumer safety advocate, remarked, “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability.” This sentiment underscores a broader issue: the accessibility of regulatory bodies to corporate leaders compared to the voices of those adversely affected by their products.
A Call for Accountability
In response to the mounting criticism, Bayer has defended the meeting and its interactions with the EPA as standard practice within regulatory processes. The company maintains that it has been transparent about its position and that discussions with regulatory bodies are not exclusive to corporate entities. However, advocates argue that the regulatory framework must be scrutinised to ensure it serves the public interest rather than corporate profitability.
The contrast between the EPA’s engagement with Bayer and its responsiveness to community concerns regarding glyphosate raises urgent questions about accountability. Advocacy groups, including Moms Across America, have voiced frustrations about the lack of attention given to the health concerns of individuals affected by glyphosate, calling into question the integrity of the regulatory process.
Why it Matters
This situation serves as a crucial reminder of the potential pitfalls when corporate interests intertwine with public health regulations. The meeting between Bayer and the EPA illustrates a concerning trend where regulatory processes may be swayed by powerful industry voices, overshadowing the rights and health of everyday citizens. As the debate over glyphosate continues, the need for transparency and accountability in regulatory practices has never been more urgent, ensuring that health and safety remain paramount in the face of corporate influence.